Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1210 + bevacizumab + oxaliplatin + capecitabine
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination regimen consisting of **SHR-1210 (camrelizumab)**, a humanized anti-PD-1 monoclonal antibody; **bevacizumab**, a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A); **oxaliplatin**, a platinum-based small molecule chemotherapeutic agent that forms DNA crosslinks; and **capecitabine**, an oral prodrug of 5-fluorouracil that inhibits DNA synthesis in proliferating tumor cells. This combination is explored primarily in oncology settings, leveraging immune checkpoint inhibition (SHR-1210), antiangiogenic blockade (bevacizumab), DNA damage (oxaliplatin), and antimetabolite chemotherapeutic activity (capecitabine), with focus on solid tumors such as metastatic colorectal and hepatocellular cancer. The regimen aims to exploit additive or synergistic effects on tumor control through immune modulation, antiangiogenesis, and cytotoxicity[2][3][4][7].
- Other names
- camrelizumab + bevacizumab + oxaliplatin + capecitabine
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SHR-1210 + bevacizumab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1210 + bevacizumab + oxaliplatin + capecitabine.